CTMX

4.56

0.44% 0.02

Dopo l'orario di chiusura: 4.55 -0.010 -0.22%

Cytomx Therapeutics Inc (CTMX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$4.54

Aprire:

$4.575

Volume 24 ore:

4.71M

Relative Volume:

0.71

Capitalizzazione di mercato:

$985.77M

Reddito:

$76.20M

Utile/perdita netta:

$-17.37M

Rapporto P/E:

501.10

EPS:

0.0091

Flusso di cassa netto:

$-75.81M

1 W Prestazione:

+7.29%

1M Prestazione:

-2.56%

6M Prestazione:

+33.72%

1 anno Prestazione:

+622.09%

Intervallo 1D:

$4.39

$4.66

Intervallo di 1 settimana:

$4.16

$4.66

Portata 52W:

$0.61

$8.21

Cytomx Therapeutics Inc Stock (CTMX) Company Profile

Nome

Cytomx Therapeutics Inc

Settore

Healthcare (1112)

Industria

Biotechnology (621)

Telefono

650.515.3185

Indirizzo

151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA

Dipendente

Cinguettio

@cytomxinc

Prossima data di guadagno

2026-03-16

Ultimi documenti SEC

CTMX's Discussions on Twitter

Compare CTMX vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
CTMX Cytomx Therapeutics Inc	4.56	981.44M	76.20M	-17.37M	-75.81M	0.0091
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-03-16	Aggiornamento	JP Morgan	Neutral → Overweight
2026-01-20	Iniziato	Guggenheim	Buy
2025-09-22	Iniziato	Cantor Fitzgerald	Overweight
2025-09-17	Ripresa	Barclays	Overweight
2025-07-31	Iniziato	Oppenheimer	Outperform
2025-05-15	Aggiornamento	H.C. Wainwright	Neutral → Buy
2025-04-14	Ripresa	Piper Sandler	Overweight
2024-05-28	Aggiornamento	Piper Sandler	Neutral → Overweight
2024-05-09	Aggiornamento	Wedbush	Neutral → Outperform
2024-05-06	Aggiornamento	Jefferies	Hold → Buy
2024-04-22	Aggiornamento	JP Morgan	Underweight → Neutral
2022-11-14	Downgrade	BMO Capital Markets	Outperform → Market Perform
2022-07-07	Downgrade	Jefferies	Buy → Hold
2022-07-07	Downgrade	Mizuho	Buy → Neutral
2022-07-07	Downgrade	Piper Sandler	Overweight → Neutral
2022-07-07	Downgrade	Wedbush	Outperform → Neutral
2022-06-24	Iniziato	BMO Capital Markets	Outperform
2022-01-18	Aggiornamento	Barclays	Underweight → Overweight
2021-11-15	Iniziato	BTIG Research	Buy
2021-05-28	Downgrade	Barclays	Equal Weight → Underweight
2021-03-29	Iniziato	JP Morgan	Overweight
2021-03-23	Aggiornamento	Jefferies	Hold → Buy
2020-09-22	Downgrade	Guggenheim	Buy → Neutral
2020-06-01	Downgrade	Jefferies	Buy → Hold
2020-05-14	Reiterato	H.C. Wainwright	Buy
2020-03-24	Aggiornamento	Wedbush	Neutral → Outperform
2020-03-04	Iniziato	Barclays	Equal Weight
2019-11-20	Iniziato	Guggenheim	Buy
2019-11-11	Downgrade	Wedbush	Outperform → Neutral
2019-06-13	Iniziato	Mizuho	Buy
2019-05-14	Iniziato	Cantor Fitzgerald	Overweight
2019-03-11	Iniziato	Barclays	Overweight
2018-11-26	Iniziato	Piper Jaffray	Overweight
2018-10-15	Iniziato	Goldman	Neutral
2018-09-13	Iniziato	H.C. Wainwright	Buy
2018-06-01	Iniziato	SunTrust	Buy
2018-01-05	Iniziato	Citigroup	Buy
2017-09-08	Iniziato	Wedbush	Outperform
2017-03-27	Iniziato	H.C. Wainwright	Buy
2017-03-02	Iniziato	Instinet	Buy
2017-01-03	Downgrade	Oppenheimer	Outperform → Perform
2015-11-02	Iniziato	Oppenheimer	Outperform

Mostra tutto

Cytomx Therapeutics Inc Borsa (CTMX) Ultime notizie

10:14 AM

Analysts bullish on CytomX Therapeutics (CTMX) as CTMX prices $250 million offering - MSN

10:14 AM

04:05 AM

CytomX Therapeutics (CTMX) making progress on key metastatic colorectal cancer treatment - MSN

04:05 AM

Apr 14, 2026